Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread

Official Title

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Keywords

Melanoma NKTR-214 Nivolumab Immunotherapy bempegaldesleukin (BEMPEG: NKTR-214) Monotherapy

Eligibility

You can join if…

Open to people ages 12 years and up

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 (adults 18 years or older)/Lansky Performance Score ≥ 80% (minors ages 12-17 only)
  • Histologically confirmed stage III (unresectable) or stage IV melanoma
  • Treatment-naive participants (ie, no prior systemic anticancer therapy for unresectable or metastatic melanoma) with the exception of prior adjuvant and/or neoadjuvant treatment for melanoma with approved agents

You CAN'T join if...

Other protocol defined inclusion/exclusion criteria apply

Locations

  • UC San Diego Moores Cancer Ctr
    La Jolla California 92093-0698 United States
  • Local Institution - 0187
    Tucson Arizona 85724 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
ID
NCT03635983
Phase
Phase 3 research study
Study Type
Interventional
Participants
At least 783 people participating
Last Updated